This article is a correction to:
Developing an Immune-Related Signature for Predicting Survival Rate and the Response to Immune Checkpoint Inhibitors in Patients With Glioma
Sibin Zhang1†
Xu Xiao1†
Yu Wang2Tianjun Song3
Chenlong Li1Hongbo Bao1
Qing Liu1Guiyin Sun1Xiaoyang Sun1Tianqi Su1Tianjiao Fu1Yujie Wang1Peng Liang1*- 1Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, China
- 2Department of Esophageal Surgery, Harbin Medical University Cancer Hospital, Harbin, China
- 3Department of Medicine II, University Hospital LMU Munich, Munich, Germany
In the published article, there was an error in Figure 2 as published. The second ROC curve in Figure 2B and the second KM curve in Figure 2C are same with the first ROC curve in Figure 2B and the first KM curve in Figure 2C, respectively. The corrected Figure 2 appears below.
FIGURE 2
FIGURE 2. Immune-related signature effectively predicts the prognosis of patients with glioma. (A) Risk score distribution, survival status and expression of 15 hub genes for glioma in low-risk and high-risk groups. (B) 1, 3 and 5-year ROC curve analyses. ROC, receiver operating characteristic. (C) K-M survival curve analyses.
In the published article, there was an error in Results, Immune-Related Signature and the Survival of Patients With Glioma, paragraph 1. This sentence previously stated: “In the TCGA training set, the under areas of 1-year, 3-year and 5-year survival were 0.88, 0.93 and 0.90”
The corrected sentence appears below:
“In the TCGA training set, the under areas of 1-year, 3-year and 5-year survival were 0.88, 0.94 and 0.93”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: glioma, bioinformatics signature, prognosis, immune enviroment, immunetherapy
Citation: Zhang S, Xiao X, Wang Y, Song T, Li C, Bao H, Liu Q, Sun G, Sun X, Su T, Fu T, Wang Y and Liang P (2022) Corrigendum: Developing an immune-related signature for predicting survival rate and the response to immune checkpoint inhibitors in patients with glioma. Front. Genet. 13:961153. doi: 10.3389/fgene.2022.961153
Received: 04 June 2022; Accepted: 11 July 2022;
Published: 17 August 2022.
Edited and reviewed by:
Richard D. Emes, University of Nottingham, United KingdomCopyright © 2022 Zhang, Xiao, Wang, Song, Li, Bao, Liu, Sun, Sun, Su, Fu, Wang and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Peng Liang, bGlhbmdwZW5nZEB5YWhvby5jb20=
†These authors have contributed equally to this work and share first authorship